SEVERE SEPSIS AND SEPTIC SHOCK Definitions, Epidemiology, and Clinical Manifestations

[1]  Anand Kumar,et al.  Genetic factors in septic shock. , 1999, JAMA.

[2]  J. Dhainaut,et al.  Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. , 1999, JAMA.

[3]  A. Flahault,et al.  Thrombocytopenia in a surgical ICU. , 1999, Chest.

[4]  R. Gaynes,et al.  Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. , 1999, Critical care medicine.

[5]  P. Galanaud,et al.  Pro- and anti-inflammatory cytokines during acute severe pancreatitis: an early and sustained response, although unpredictable of death. Parisian Study Group on Acute Pancreatitis. , 1999, Critical care medicine.

[6]  P. Barie,et al.  Multivariate analysis of 9 disease-associated variables for outcome prediction in patients with sepsis. , 1998, Archives of surgery.

[7]  J. Vincent,et al.  Has the mortality of septic shock changed with time. , 1998, Critical care medicine.

[8]  O. Kemmotsu,et al.  Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. , 1998, Critical care medicine.

[9]  C. Chopin,et al.  EFFECTS OF A COMBINED ANTITHROMBIN III AND PROTEIN C SUPPLEMENTATION IN PORCINE ACUTE ENDOTOXIC SHOCK , 1998, Shock.

[10]  J. Parrillo,et al.  RANDOMIZED, BLINDED, PLACEBO‐CONTROLLED TRIAL OF TISSUE FACTOR PATHWAY INHIBITOR IN PORCINE SEPTIC SHOCK , 1998, Shock.

[11]  C. Dinarello,et al.  Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. , 1997, Chest.

[12]  J. Vincent,et al.  New therapies in sepsis. , 1997, Chest.

[13]  V. Praloran,et al.  Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. , 1997, The American journal of medicine.

[14]  D. Bates,et al.  Epidemiology of sepsis syndrome in 8 academic medical centers. , 1997, JAMA.

[15]  R. Bone,et al.  Sepsis: a new hypothesis for pathogenesis of the disease process. , 1997, Chest.

[16]  C. Natanson,et al.  Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. , 1997, Critical care medicine.

[17]  R. Bone.  Why sepsis trials fail. , 1996, JAMA.

[18]  C. Bolton,et al.  Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. , 1996, Critical care medicine.

[19]  N. Webster,et al.  The immuno-inflammatory cascade. , 1996, British journal of anaesthesia.

[20]  C. Marsh,et al.  The pathogenesis of sepsis. Factors that modulate the response to gram-negative bacterial infection. , 1996, Clinics in chest medicine.

[21]  R. Auckenthaler,et al.  Bedside prediction of mortality from bacteremic sepsis. A dynamic analysis of ICU patients. , 1996, American journal of respiratory and critical care medicine.

[22]  François Gouin,et al.  Incidence, Risk Factors, and Outcome of Severe Sepsis and Septic Shock in Adults: A Multicenter Prospective Study in Intensive Care Units , 1995 .

[23]  F Doyon,et al.  Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. , 1995, JAMA.

[24]  G. Ramsay,et al.  Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. , 1995, JAMA.

[25]  E Nauenberg,et al.  Long-term survival after intensive care unit admission with sepsis. , 1995, Critical care medicine.

[26]  Janelle Klar,et al.  Customized probability models for early severe sepsis in adult intensive care patients. Intensive Care Unit Scoring Group. , 1995, JAMA.

[27]  D. Pittet,et al.  The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. , 1995, JAMA.

[28]  B. Guidet,et al.  Endotoxemia and bacteremia in patients with sepsis syndrome in the intensive care unit. , 1994, Chest.

[29]  C. Natanson,et al.  Selected Treatment Strategies for Septic Shock Based on Proposed Mechanisms of Pathogenesis , 1994, Annals of Internal Medicine.

[30]  R. Balk.  Septic shock: pathophysiology , 1994 .

[31]  S. Lemeshow,et al.  A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study , 1993 .

[32]  R. Bone,et al.  Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome , 1993, Annals of Internal Medicine.

[33]  C J Fisher,et al.  The clinical evaluation of new drugs for sepsis. A prospective study design based on survival analysis. , 1993, JAMA.

[34]  J. Vincent,et al.  Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. , 1993, Chest.

[35]  J. Gelfand,et al.  Cytokines and sepsis: pathophysiology and therapy. , 1993, New horizons.

[36]  R. Bone,et al.  Modulators of coagulation. A critical appraisal of their role in sepsis. , 1992, Archives of internal medicine.

[37]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[38]  G. Gutierrez,et al.  Comparison of gastric intramucosal pH with measures of oxygen transport and consumption in critically ill patients , 1992, Critical care medicine.

[39]  R. Bone.  A critical evaluation of new agents for the treatment of sepsis. , 1991, JAMA.

[40]  R. Bone,et al.  The pathogenesis of sepsis. , 1991, Annals of internal medicine.

[41]  R. Bone,et al.  Gram-negative sepsis. Background, clinical features, and intervention. , 1991, Chest.

[42]  F. Pálizas,et al.  Gastric mucosal pH as a prognostic index of mortality in critically ill patients , 1991, Critical care medicine.

[43]  Michael F. Wilson,et al.  Impact of encephalopathy on mortality in the sepsis syndrome. The Veterans Administration Systemic Sepsis Cooperative Study Group. , 1990, Critical care medicine.

[44]  F. Ognibene,et al.  Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. , 1990, Annals of internal medicine.

[45]  T. Clemmer,et al.  Sepsis syndrome: a valid clinical entity , 1989 .

[46]  W. R. Mccabe,et al.  Gram-negative bacteremia: IV. Re-evaluation of clinical features and treatment in 612 patients , 1980 .

[47]  W. R. Mccabe,et al.  Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients. , 1980, The American journal of medicine.

[48]  K. Katsouyanni,et al.  The regional production of cytokines and lactate in sepsis-related multiple organ failure. , 1997, American journal of respiratory and critical care medicine.

[49]  F. Ognibene,et al.  clinical investigations in critical care Right Ventricular Dysfunction and Dilatation , Similar to Left Ventricular Changes , Characterize the Cardiac Depression of Septic Shock in Humans * , 2006 .

[50]  R. Bone,et al.  The septic syndrome. Definition and clinical implications. , 1989, Critical care clinics.